<DOC>
	<DOCNO>NCT01174940</DOCNO>
	<brief_summary>To study effect ECP Uvadex® conjunction standard myeloablative conditioning regimen incidence acute chronic GvHD patient undergo allogeneic relate unrelated BMT PBSC transplant , treatment hematologic lymphoproliferative malignancy .</brief_summary>
	<brief_title>Test Extracorporeal Photopheresis ( ECP ) Treatment Before/After Allogeneic Bone Marrow Transplant ( BMT ) Peripheral Blood Stem Cell ( PBSC ) Transplant Prevent Graft Versus Host Disease</brief_title>
	<detailed_description>This study test concept use ECP treatment prior allogeneic bone marrow transplant ( BMT ) peripheral blood stem cell ( PBSC ) transplant prevent development GvHD . This study design detect specific treatment effect . However , statement outcome study possible . A sample size n = 21 patient could detect statistically significant difference expect rate GvHD untreated population , 60 % , hypothesize rate , 30 % , matched-unrelated recipient . This calculation base one-sample , two-sided chi-square test 5 % level significance 80 % power . Patients receive ECP day -10 day -8 transplant day engraftment absolute neutrophil count ( ANC &gt; 500 ) day 90 transplant . Patients enter study receive BMT PBSC transplant donor match unrelated ( 8/10 10/10 match ) . Rates acute GvHD chronic GvHD occur patient 50-70 % matched-unrelated donor transplant . The choice sample size 21 patient . The analysis determine favorable trend treatment effect . Comparison survival , rate acute chronic GvHD make historical control undergone similar myeloablative transplant unrelated donor .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>Patients eligible diagnosis one follow hematologic lymphoproliferative malignancy treatment option would allogeneic BMT PBSC transplant : acute myelogenous leukemia chronic myelogenous leukemia acute lymphocytic/blastic leukemia chronic lymphocytic leukemia myelodysplastic syndrome nonHodgkin 's lymphoma ( expect survival &gt; 60 day ) Hodgkin 's disease ( expect survival &gt; 60 day ) Patients candidate standard allogeneic BMT patient candidate standard allogeneic PBSC transplant . Patients must suitable HLA molecular match ( 8/10 ) relate unrelated donor . Patients must physically psychologically capable undergo BMT PBSC transplant attendant period strict isolation . Patients must test negative human immunodeficiency virus ( HIV ) . Patients must present evidence active ongoing infection . Patients must adequate renal , hepatic , pulmonary , cardiac function enable patient tolerate extracorporeal volume shift associate ECP , determine physician 's clinical judgment . Platelets ≥ 20,000/cmm . Patients ≥ 18 year age . Weight ≥ 40 kg ( 88 lb ) . Systolic Blood Pressure ≥ 90 mm Hg patient sit position five minute . Women childbearing potential must agree use reliable method birth control duration study . Patients must willing comply study procedure . Signed date informed consent must obtain prior conduct study procedure . The parent legal guardian minor must also provide write informed consent . Exclusion Criteria Patients receive prior allogeneic BMT PBSC transplant . Hypersensitivity allergy psoralen ( methoxsalen ) . Contraindication radiation , cyclophosphamide , CSA , Busulphan MTX . Hypersensitivity allergy heparin citrate product . ( If hypersensitive allergic one two product , exclusion apply product strictly use patient . ) Patients whose treatment require donor lymphocyte infusion day 100 posttransplant . Participation another clinical trial prevention GvHD within 7 day prior patient enrollment concurrent participation clinical study . Active gastrointestinal bleeding . Females pregnant lactating . Previous treatment ECP .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>myelogenous leukemia</keyword>
	<keyword>lymphocytic leukemia</keyword>
	<keyword>lymphoblastic leukemia</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>non-Hodgkin 's lymphoma</keyword>
	<keyword>Hodgkin 's disease</keyword>
</DOC>